Organon & Co. (NYSE:OGN) Shares Acquired by EMC Capital Management

EMC Capital Management lifted its holdings in Organon & Co. (NYSE:OGN) by 343.9% during the fourth quarter, Holdings Channel reports. The fund owned 13,831 shares of the company’s stock after buying an additional 10,715 shares during the quarter. EMC Capital Management’s holdings in Organon & Co. were worth $206,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in OGN. Pacer Advisors Inc. boosted its holdings in Organon & Co. by 94,482.1% in the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock valued at $166,391,000 after purchasing an additional 11,140,388 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Organon & Co. by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 4,248,108 shares of the company’s stock valued at $81,288,000 after buying an additional 82,220 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Organon & Co. by 35.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company’s stock valued at $63,570,000 after buying an additional 875,128 shares during the period. Thompson Siegel & Walmsley LLC boosted its stake in shares of Organon & Co. by 6.4% in the third quarter. Thompson Siegel & Walmsley LLC now owns 2,262,379 shares of the company’s stock worth $43,279,000 after buying an additional 136,457 shares during the last quarter. Finally, Private Management Group Inc. grew its holdings in Organon & Co. by 1.8% during the third quarter. Private Management Group Inc. now owns 1,893,868 shares of the company’s stock worth $36,230,000 after acquiring an additional 34,026 shares during the period. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, TD Cowen raised Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $21.33.

Organon & Co. Price Performance

NYSE:OGN opened at $15.97 on Friday. Organon & Co. has a 52 week low of $13.87 and a 52 week high of $23.10. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The stock has a market capitalization of $4.11 billion, a PE ratio of 3.17, a price-to-earnings-growth ratio of 0.89 and a beta of 0.76. The stock’s 50-day moving average price is $15.46 and its 200-day moving average price is $17.97.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The business had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The business’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.78 EPS. As a group, equities analysts expect that Organon & Co. will post 3.83 EPS for the current fiscal year.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.